These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 36150744)

  • 1. Mitigating the prevalence and function of myeloid-derived suppressor cells by redirecting myeloid differentiation using a novel immune modulator.
    Oliver L; Alvarez R; Diaz R; Valdés A; Colligan SH; Nemeth MJ; Twum DYF; Fernández A; Fernández-Medina O; Carlson LM; Yu H; Eng KH; Hensen ML; Rábade-Chediak ML; Fernández LE; Lee KP; Perez L; Muhitch JB; Mesa C; Abrams SI
    J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36150744
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Granulocyte Progenitor Stage Is a Key Target of IRF8-Mediated Regulation of Myeloid-Derived Suppressor Cell Production.
    Netherby CS; Messmer MN; Burkard-Mandel L; Colligan S; Miller A; Cortes Gomez E; Wang J; Nemeth MJ; Abrams SI
    J Immunol; 2017 May; 198(10):4129-4139. PubMed ID: 28356386
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Decidua-derived granulocyte macrophage colony-stimulating factor induces polymorphonuclear myeloid-derived suppressor cells from circulating CD15+ neutrophils.
    Li C; Chen C; Kang X; Zhang X; Sun S; Guo F; Wang Q; Kou X; Bai W; Zhao A
    Hum Reprod; 2020 Dec; 35(12):2677-2691. PubMed ID: 33067638
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interferon regulatory factor 4 (IRF4) controls myeloid-derived suppressor cell (MDSC) differentiation and function.
    Nam S; Kang K; Cha JS; Kim JW; Lee HG; Kim Y; Yang Y; Lee MS; Lim JS
    J Leukoc Biol; 2016 Dec; 100(6):1273-1284. PubMed ID: 27601624
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Very small size proteoliposomes abrogate cross-presentation of tumor antigens by myeloid-derived suppressor cells and induce their differentiation to dendritic cells.
    Fernández A; Oliver L; Alvarez R; Hernández A; Raymond J; Fernández LE; Mesa C
    J Immunother Cancer; 2014; 2():5. PubMed ID: 24829762
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Visualization and quantification of
    Hoffmann SHL; Reck DI; Maurer A; Fehrenbacher B; Sceneay JE; Poxleitner M; Öz HH; Ehrlichmann W; Reischl G; Fuchs K; Schaller M; Hartl D; Kneilling M; Möller A; Pichler BJ; Griessinger CM
    Theranostics; 2019; 9(20):5869-5885. PubMed ID: 31534525
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanisms overseeing myeloid-derived suppressor cell production in neoplastic disease.
    Netherby CS; Abrams SI
    Cancer Immunol Immunother; 2017 Aug; 66(8):989-996. PubMed ID: 28224211
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Bacterial and Ganglioside-based Nanoparticle Initiates Reprogramming of Macrophages and Promotes Antitumor Phenotypes.
    Alvarez-Arzola R; Oliver L; Messmer MM; Twum DYF; Lee KP; Muhitch JB; Mesa C; Abrams SI
    J Immunol; 2024 Feb; 212(3):475-486. PubMed ID: 38117752
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aryl hydrocarbon receptor activation drives polymorphonuclear myeloid-derived suppressor cell response and efficiently attenuates experimental Sjögren's syndrome.
    Wei Y; Peng N; Deng C; Zhao F; Tian J; Tang Y; Yu S; Chen Y; Xue Y; Xiao F; Zhou Y; Li X; Zou H; Rui K; Lin X; Lu L
    Cell Mol Immunol; 2022 Dec; 19(12):1361-1372. PubMed ID: 36369368
    [TBL] [Abstract][Full Text] [Related]  

  • 10. VSSP abrogates murine ovarian tumor-associated myeloid cell-driven immune suppression and induces M1 polarization in tumor-associated macrophages from ovarian cancer patients.
    Khan ANH; Emmons TR; Magner WJ; Alqassim E; Singel KL; Ricciuti J; Eng KH; Odunsi K; Tomasi TB; Lee K; Abrams SI; Mesa C; Segal BH
    Cancer Immunol Immunother; 2022 Oct; 71(10):2355-2369. PubMed ID: 35166871
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PMN-MDSCs Enhance CTC Metastatic Properties through Reciprocal Interactions via ROS/Notch/Nodal Signaling.
    Sprouse ML; Welte T; Boral D; Liu HN; Yin W; Vishnoi M; Goswami-Sewell D; Li L; Pei G; Jia P; Glitza-Oliva IC; Marchetti D
    Int J Mol Sci; 2019 Apr; 20(8):. PubMed ID: 31003475
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenic therapy.
    Finke J; Ko J; Rini B; Rayman P; Ireland J; Cohen P
    Int Immunopharmacol; 2011 Jul; 11(7):856-61. PubMed ID: 21315783
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circulating Myeloid-Derived Suppressor Cell Subsets in Patients with Colorectal Cancer - Exploratory Analysis of Their Biomarker Potential.
    Fědorová L; Pilátová K; Selingerová I; Bencsiková B; Budinská E; Zwinsová B; Brychtová V; Langrová M; Šefr R; Valík D; Zdražilová Dubská L
    Klin Onkol; 2018; 31(Suppl 2):88-92. PubMed ID: 31023030
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of tumor-induced myeloid-derived suppressor cell function by a nanoparticulated adjuvant.
    Fernández A; Mesa C; Marigo I; Dolcetti L; Clavell M; Oliver L; Fernández LE; Bronte V
    J Immunol; 2011 Jan; 186(1):264-74. PubMed ID: 21135171
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interferon-γ-Induced Myeloid-Derived Suppressor Cells Aggravate Kidney Ischemia-Reperfusion Injury by Regulating Innate Immune Cells.
    Ji J; Zhuang Y; Lin Z; Jiang Y; Wang W; Zhang X
    Nephron; 2022; 146(1):99-109. PubMed ID: 34569551
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relevance of Interferon Regulatory Factor-8 Expression in Myeloid-Tumor Interactions.
    Abrams SI; Netherby CS; Twum DY; Messmer MN
    J Interferon Cytokine Res; 2016 Jul; 36(7):442-53. PubMed ID: 27379866
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expansion of PMN-myeloid derived suppressor cells and their clinical relevance in patients with oral squamous cell carcinoma.
    Zhong LM; Liu ZG; Zhou X; Song SH; Weng GY; Wen Y; Liu FB; Cao DL; Liu YF
    Oral Oncol; 2019 Aug; 95():157-163. PubMed ID: 31345384
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tristetraprolin limits age-related expansion of myeloid-derived suppressor cells.
    Kwack KH; Zhang L; Kramer ED; Thiyagarajan R; Lamb NA; Arao Y; Bard JE; Seldeen KL; Troen BR; Blackshear PJ; Abrams SI; Kirkwood KL
    Front Immunol; 2022; 13():1002163. PubMed ID: 36263047
    [TBL] [Abstract][Full Text] [Related]  

  • 19. On the origin of myeloid-derived suppressor cells.
    Millrud CR; Bergenfelz C; Leandersson K
    Oncotarget; 2017 Jan; 8(2):3649-3665. PubMed ID: 27690299
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunoglobulin-like transcript 3 is expressed by myeloid-derived suppressor cells and correlates with survival in patients with non-small cell lung cancer.
    de Goeje PL; Bezemer K; Heuvers ME; Dingemans AC; Groen HJ; Smit EF; Hoogsteden HC; Hendriks RW; Aerts JG; Hegmans JP
    Oncoimmunology; 2015 Jul; 4(7):e1014242. PubMed ID: 26140237
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.